Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now small index

Li-Fraumeni Syndrome clinical trials

5 of 7 indexed Li-Fraumeni Syndrome trials are currently recruiting.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Li-Fraumeni Syndrome: 7 US clinical trials tracked, 5 recruiting.

Li-Fraumeni Syndrome is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. The most active sponsor is Dana-Farber Cancer Institute, running 2 of these trials.

Enrollment posture brief

Registry condition li-fraumeni-syndrome

OPEN 5 | RECR 71% | LATE 0 | EARLY 0 | RANK #2497 | SPON 2

Nearest open-share peer: Advanced Endometrial Carcinoma (71% recruiting · 7 trials)

ACL Tear71.4%Li-Fraumeni Syndrome (this)71%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Li-Fraumeni Syndrome

Li-Fraumeni Syndrome lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Li-Fraumeni Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Li-Fraumeni Syndrome is recruiting above its size-band peers.

    5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Li-Fraumeni Syndrome research.

    Dana-Farber Cancer Institute accounts for 2 of 7 trials (28.6%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Li-Fraumeni Syndrome enrolment sits around 500 participants.

    Median target enrolment is 500 among the 7 trials that report a genuine target (sentinel values excluded). 1 of those (14.3%) plan for fewer than 100 participants.

  4. Li-Fraumeni Syndrome research leans observational.

    1 interventional and 6 observational studies make up this index (14.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Li-Fraumeni Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Whole Body MRI Device
1 trials
Data and Specimen Collection Genetic
1 trials
NSR IDE-MRI: Research pulse sequences Device
1 trials
No Intervention Other
1 trials
Questionnaire Administration Other
1 trials

US sites by state

Facility locations filed on Li-Fraumeni Syndrome trials. A trial with sites in several states counts in each.

Maryland 3 trials
Pennsylvania 2 trials
Massachusetts 2 trials
Texas 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Li-Fraumeni Syndrome page

7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Li-Fraumeni Syndrome condition card totals 7 registered trials; most-linked intervention Whole Body MRI; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.